Aspire Bariatrics Announces Aspireassist Receives Australian TGA Approval And First Commercial Cases Performed In Australia

Published: Jun 22, 2017

KING OF PRUSSIA, Pa., June 21, 2017 (GLOBE NEWSWIRE) -- Aspire Bariatrics, Inc., a commercial-stage medical device company announced today that it received approval to market the AspireAssist®, a novel device for the treatment of obesity, in Australia by the Therapeutic Goods Administration (TGA) and that the first cases using the AspireAssist have been performed in Australia.

“Until the AspireAssist, the only available option to treat obesity in people with severe obesity has been bariatric surgery. Although effective in weight loss, bariatric surgery is not favored by many patients because of its irreversibility and their concern about complications,” said Dr. Patrick Walsh, BSC, MB CHB, FRACP, of Intensiv Weight Loss of Queensland, Australia. “The AspireAssist provides comparable weight loss to bariatric surgery but is reversible, with few and minor complications.”

“We are pleased to be able to offer the AspireAssist as a treatment option for people with obesity in Australia. Australia has been one of the most forward-thinking countries in the treatment of obesity and we look forward to expanding our presence there,” said Katherine Crothall, PhD, President & CEO of Aspire Bariatrics.

About Aspire Bariatrics, Inc.
Aspire Bariatrics is a commercial-stage medical device company with a minimally-invasive, endoscopic device, the AspireAssist®, to treat obesity. In June 2016, the Company received premarket approval (PMA) from the FDA. AspireAssist Therapy is an alternative to bariatric surgery, providing comparable weight loss, but with far better safety, complete reversibility, and at a significantly lower cost than bariatric surgery. The therapy provides a holistic approach to patient development of improved eating behaviors, reflected in significant improvement in quality of life and high satisfaction with the therapy.

Contact for Investors and Media
Kathy Crothall, PhD
President and CEO
(610) 590-1568

Back to news